Literature DB >> 21403662

Complications associated with chemotherapy in testicular cancer management.

Chunkit Fung1, David J Vaughn.   

Abstract

Testicular cancer is the most common solid tumor among men aged 15-35 years. The introduction of cisplatin-based chemotherapy has resulted in a cure rate of over 95% for men with testicular cancer, which has put increased emphasis on understanding the morbidity associated with chemotherapy. Hematological, gastrointestinal, gonadal, otological, renal, neurological, and pulmonary toxicities are the most common acute adverse effects. Although most patients recover, some of these effects can persist after the chemotherapy regimen has been completed and can become chronic problems. The late complications associated with cisplatin-based chemotherapy include secondary malignancies, cardiovascular disease, avascular necrosis, and cognitive impairment. Late complications can have considerable effects on survival and quality of life, so close monitoring of patients is critical for the early diagnosis of late adverse effects and to limit associated damage. All patients should adopt a healthy lifestyle and follow age-appropriate cancer screening programs. Hormonal supplementation should be considered for those with a low testosterone level, in order to reduce the risk of sexual dysfunction and metabolic syndrome. Prompt diagnosis of avascular necrosis is essential, and it should be considered in the differential diagnosis for any long-term testicular cancer survivor complaining of hip pain. Finally, sperm cryopreservation should be discussed with all patients before chemotherapy is initiated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21403662     DOI: 10.1038/nrurol.2011.26

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  135 in total

1.  A prospective study of neuropsychological functioning in testicular cancer patients.

Authors:  T Skaali; S D Fosså; S Andersson; M Cvancarova; C W Langberg; G Lehne; A A Dahl
Journal:  Ann Oncol       Date:  2010-11-03       Impact factor: 32.976

2.  Long-term renal function after treatment for malignant germ-cell tumours.

Authors:  S D Fosså; N Aass; M Winderen; O P Börmer; D R Olsen
Journal:  Ann Oncol       Date:  2002-02       Impact factor: 32.976

Review 3.  Lung damage from cytotoxic drugs.

Authors:  C H Collis
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

5.  The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer.

Authors:  Janine Nuver; Andries J Smit; Bruce H R Wolffenbuttel; Wim J Sluiter; Harald J Hoekstra; Dirk T Sleijfer; Jourik A Gietema
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

6.  Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries.

Authors:  Lorenzo Richiardi; Ghislaine Scélo; Paolo Boffetta; Kari Hemminki; Eero Pukkala; Jorgen H Olsen; Elisabete Weiderpass; Elizabeth Tracey; David H Brewster; Mary L McBride; Erich V Kliewer; Jon M Tonita; Vera Pompe-Kirn; Chia Kee-Seng; Jon G Jonasson; Carmen Martos; Paul Brennan
Journal:  Int J Cancer       Date:  2007-02-01       Impact factor: 7.396

7.  Fecundity and twinning rates as measures of fertility before diagnosis of germ-cell testicular cancer.

Authors:  Lorenzo Richiardi; Olof Akre; Scott M Montgomery; Mats Lambe; Ulrik Kvist; Anders Ekbom
Journal:  J Natl Cancer Inst       Date:  2004-01-21       Impact factor: 13.506

8.  Mortality after cure of testicular seminoma.

Authors:  Gunar K Zagars; Matthew T Ballo; Andrew K Lee; Sara S Strom
Journal:  J Clin Oncol       Date:  2004-01-15       Impact factor: 44.544

9.  Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.

Authors:  G Daugaard; N Rossing; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model.

Authors:  E Cvitkovic; J Spaulding; V Bethune; J Martin; W F Whitmore
Journal:  Cancer       Date:  1977-04       Impact factor: 6.860

View more
  14 in total

1.  Impact of treatment exposures on cardiovascular risk and insulin resistance in childhood cancer survivors.

Authors:  K Scott Baker; Eric J Chow; Pamela J Goodman; Wendy M Leisenring; Andrew C Dietz; Joanna L Perkins; Lisa Chow; Alan Sinaiko; Antoinette Moran; Anna Petryk; Julia Steinberger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-05       Impact factor: 4.254

2.  TDRG1 regulates chemosensitivity of seminoma TCam-2 cells to cisplatin via PI3K/Akt/mTOR signaling pathway and mitochondria-mediated apoptotic pathway.

Authors:  Yu Gan; Yong Wang; Zhengyu Tan; Jun Zhou; Riko Kitazawa; Xianzhen Jiang; Yuxin Tang; Jianfu Yang
Journal:  Cancer Biol Ther       Date:  2016-04-22       Impact factor: 4.742

Review 3.  Adverse effects of common medications on male fertility.

Authors:  Mary K Samplaski; Ajay K Nangia
Journal:  Nat Rev Urol       Date:  2015-06-23       Impact factor: 14.432

4.  Lysine methylation represses p53 activity in teratocarcinoma cancer cells.

Authors:  Jiajun Zhu; Zhixun Dou; Morgan A Sammons; Arnold J Levine; Shelley L Berger
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-17       Impact factor: 11.205

5.  Chemotherapy accelerates age-related development of tauopathy and results in loss of synaptic integrity and cognitive impairment.

Authors:  Angie C A Chiang; Xiaojiao Huo; Annemieke Kavelaars; Cobi J Heijnen
Journal:  Brain Behav Immun       Date:  2019-04-03       Impact factor: 7.217

6.  Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk.

Authors:  John Charles A Lacson; Joshua D Carroll; Ellenie Tuazon; Esteban J Castelao; Leslie Bernstein; Victoria K Cortessis
Journal:  Cancer       Date:  2012-09-10       Impact factor: 6.860

7.  Prospectively Identified Incident Testicular Cancer Risk in a Familial Testicular Cancer Cohort.

Authors:  Anand Pathak; Charleen D Adams; Jennifer T Loud; Kathryn Nichols; Douglas R Stewart; Mark H Greene
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-08-11       Impact factor: 4.254

8.  Selective GPER activation decreases proliferation and activates apoptosis in tumor Leydig cells.

Authors:  A Chimento; I Casaburi; M Bartucci; M Patrizii; R Dattilo; P Avena; S Andò; V Pezzi; R Sirianni
Journal:  Cell Death Dis       Date:  2013-08-01       Impact factor: 8.469

9.  Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF).

Authors:  Chunkit Fung; David J Vaughn; Nandita Mitra; Stephanie L Ciosek; Saran Vardhanabhuti; Katherine L Nathanson; Peter A Kanetsky
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-13       Impact factor: 5.555

Review 10.  Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis.

Authors:  Sigrid Marie Kraggerud; Christina E Hoei-Hansen; Sharmini Alagaratnam; Rolf I Skotheim; Vera M Abeler; Ewa Rajpert-De Meyts; Ragnhild A Lothe
Journal:  Endocr Rev       Date:  2013-04-10       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.